Objectives: To investigate the clinical and microbiological features in the patients with community-acquired acute bacterial prostatitis (CA-ABP), as well as factors that affect fluoroquinolone resistance. Methods: A retrospective analysis was performed of 209 patients hospitalized for antibiotic treatment of CA-ABP. We investigated patient age, body mass index, underlying diseases, recurrence, prostate-related factors and results of urine culture examination and antibiotic sensitivity tests. Results: Seventeen patients (8.1%) had fluoroquinolone-resistant bacterial colonies. When we divided the subjects into groups according to the fluoroquinolone resistance, the group with resistant bacteria was significantly older, had larger prostates and had greater residual urine volumes. Bacteria were identified in 127 of 209 patients (60.8%), and the most commonly cultured included Escherichia coli (43.5%). The sensitivity of the cultured bacteria to fluoroquinolones was high compared to trimethoprim/sulfamethoxazole and gentamicin, but similar to cefotaxime. The bacteria were more sensitive to amikacin and imipenem than to fluoroquinolone. The multivariate analysis revealed that prostate volume ≥40 ml (p = 0.024) and residual urine volume >100 ml (p = 0.004) were independent predictive factors for fluoroquinolone resistance. Conclusions: Fluoroquinolone monotherapy might be an effective treatment in CA-ABP. However, combination antibiotic therapy is recommended in cases with prostate volume ≥40 ml or residual urine volume >100 ml, because fluoroquinolone resistance can occur.

Keywords:
Acute bacterial prostatitis, Community acquired infection, Resistance, Empirical therapy, Fluoroquinolone
1.
Krieger JN, Lee SW, Jeon J, Cheah PY, Liong ML, Riley DE: Epidemiology of prostatitis. Int J Antimicrob Agents 2008;31(suppl 1):S85-S90.
2.
Decaestecker K, Oosterlinck W: Transurethral resection of the prostate in recurrent acute bacterial prostatitis. Urol Int 2015;94:442-444.
3.
Etienne M, Chavanet P, Sibert L, Michel F, Levesque H, Lorcerie B, Doucet J, Pfitzenmeyer P, Caron F: Acute bacterial prostatitis: heterogeneity in diagnostic criteria and management. Retrospective multicentric analysis of 371 patients diagnosed with acute prostatitis. BMC Infect Dis 2008;8:12.
4.
Schaeffer AJ: Diagnosis and treatment of prostatic infections. Urology 1990;36(5 suppl):13-17.
5.
Ha US, Kim ME, Kim CS, Shim BS, Han CH, Lee SD, Cho YH: Acute bacterial prostatitis in Korea: clinical outcome, including symptoms, management, microbiology and course of disease. Int J Antimicrob Agents 2008;31(suppl 1):S96-S101.
6.
Kahlmeter G, Poulsen HO: Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: the ECO· SENS study revisited. Int J Antimicrob Agents 2012;39:45-51.
7.
Lim SK, Park IW, Lee WG, Kim HK, Choi YH: Change of antimicrobial susceptibility among Escherichia coli strains isolated from female patients with community-onset acute pyelonephritis. Yonsei Med J 2012;53:164-171.
8.
Shin J, Kim J, Wie SH, Cho YK, Lim SK, Shin SY, Yeom JS, Lee JS, Kweon KT, Lee H, Cheong HJ, Park SH, Park DW, Ryu SY, Chung MH, Yoo S, Pai H: Fluoroquinolone resistance in uncomplicated acute pyelonephritis: epidemiology and clinical impact. Microb Drug Resist 2012;18:169-175.
9.
Kim B, Kim J, Seo MR, Wie SH, Cho YK, Lim SK, Lee JS, Kwon KT, Lee H, Cheong HJ, Park DW, Ryu SY, Chung MH, Ki M, Pai H: Clinical characteristics of community-acquired acute pyelonephritis caused by ESBL-producing pathogens in South Korea. Infection 2013;41:603-612.
10.
Kim JW, Oh MM, Bae JH, Kang SH, Park HS, Moon du G: Clinical and microbiological characteristics of spontaneous acute prostatitis and transrectal prostate biopsy-related acute prostatitis: is transrectal prostate biopsy-related acute prostatitis a distinct acute prostatitis category? J Infect Chemother 2015;21:434-437.
11.
Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, Briggs JP, Lamm W, Clark C, MacFarquhar J, Walton AL, Reller LB, Sexton DJ: Health care - associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 2002;137:791-797.
12.
Cohen-Nahum K, Saidel-Odes L, Riesenberg K, Schlaeffer F, Borer A: Urinary tract infections caused by multi-drug resistant Proteus mirabilis: risk factors and clinical outcomes. Infection 2010;38:41-46.
13.
van der Starre WE, van Nieuwkoop C, Paltansing S, van't Wout JW, Groeneveld GH, Becker MJ, Koster T, Wattel-Louis GH, Delfos NM, Ablij HC, Leyten EM, Blom JW, van Dissel JT: Risk factors for fluoroquinolone-resistant Escherichia coli in adults with community-onset febrile urinary tract infection. J Antimicrob Chemother 2011;66:650-656.
14.
Colodner R, Kometiani I, Chazan B, Raz R: Risk factors for community-acquired urinary tract infection due to quinolone-resistant E. coli. Infection 2008;36:41-45.
15.
Killgore KM, March KL, Guglielmo BJ: Risk factors for community-acquired ciprofloxacin-resistant Escherichia coli urinary tract infection. Ann Pharmacother 2004;38:1148-1152.
16.
Lin CY, Huang SH, Chen TC, Lu PL, Lin WR, Chen YH: Risk factors of ciprofloxacin resistance in urinary Escherichia coli isolates. J Microbiol Immunol Infect 2008;41:325-331.
17.
Vallés J, Calbo E, Anoro E, Fontanals D, Xercavins M, Espejo E, Serrate G, Freixas N, Morera MA, Font B, Bella F, Segura F, Garau J: Bloodstream infections in adults: importance of healthcare-associated infections. J Infect 2008;56:27-34.
18.
Carratalà J, Mykietiuk A, Fernández-Sabé N, Suárez C, Dorca J, Verdaguer R, Manresa F, Gudiol F: Health care-associated pneumonia requiring hospital admission: epidemiology, antibiotic therapy, and clinical outcomes. Arch Intern Med 2007;167:1393-1399.
19.
Goto T, Makinose S, Ohi Y, Yamauchi D, Kayajima T, Nagayama K, Hayami H: Diffusion of piperacillin, cefotiam, minocycline, amikacin and ofloxacin into the prostate. Int J Urol 1998;5:243-246.
20.
Brede CM, Shoskes DA: The etiology and management of acute prostatitis. Nat Rev Urol 2011;8:207-212.
21.
Wagenlehner FM, Weidner W, Pilatz A, Naber KG: Urinary tract infections and bacterial prostatitis in men. Curr Opin Infect Dis 2014;27:97-101.
22.
Kim SH, Jung KI, Koh JS, Min KO, Cho SY, Kim HW: Lower urinary tract symptoms in benign prostatic hyperplasia patients: orchestrated by chronic prostatic inflammation and prostatic calculi? Urol Int 2013;90:144-149.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.